# Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

> **NCT06161272** · PHASE2 · UNKNOWN · sponsor: **Guangxi Medical University** · enrollment: 80 (estimated)

## Conditions studied

- Ovarian Cancer
- High Grade Serous Adenocarcinoma of Ovary
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Fluzoparib
- **DRUG:** Fluzoparib+Apatinib

## Key facts

- **NCT ID:** NCT06161272
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-10
- **Primary completion:** 2025-03-10
- **Final completion:** 2026-01-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161272, "Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06161272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*